|
[1]
|
Zhou, Y., Liu, Y., Zhang, J., et al. (2019) Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-Mutant Gliomas. Translational Oncology, 13, 125-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Aasland, D., Götzinger, L., Hauck, L., et al. (2019) Te-mozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. Cancer Research, 79, 99-113. [Google Scholar] [CrossRef]
|
|
[3]
|
Cloughesy, T.F., Mochizuki, A.Y., Orpilla, J.R., et al. (2019) Neoadjuvant Anti-PD-1 Immunotherapy Promotes a Survival Benefit with Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma. Nature Medicine, 25, 477-486.
|
|
[4]
|
Eskilsson, E., Rosland, G.V., Talasila, K.M., et al. (2016) EGFRvIII Mutations Can Emerge as Late and Heterogenous Events in Glioblastoma Development and Promote Angiogenesis through Src Activation. Neuro-Oncology, 18, 1644-1655.
|
|
[5]
|
Szabo, E., Schneider, H., Seystahl, K., et al. (2016) Autocrine VEGFR1 and VEGFR2 Signaling Promotes Survival in Human Glioblastoma Models in Vitro and in Vivo. Neuro-Oncology, 18, 1242-1252. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Jiang, Y., Zhou, J., Zou, D., et al. (2019) Overexpression of Limb-Bud and Heart (LBH) Promotes Angiogenesis in Human Glioma via VEGFA-Mediated ERK Signalling under Hypoxia. EBio Medicine, 48, 36-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Turkowski, K., Brandenburg, S., Mueller, A., et al. (2018) VEGF as a Modulator of the Innate Immune Response in Glioblastoma. Glia, 66, 161-174. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Friedman, H.S., Prados, M.D., Wen, P.Y., et al. (2009) Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 4733-4740. [Google Scholar] [CrossRef]
|
|
[9]
|
Cloughesy, T.F., Brenner, A., de Groot, J.F., et al. (2019) A Randomized Controlled Phase III Study of VB-111 Combined with Bevacizumab vs Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma (GLOBE). Neuro-Oncology, noz232.
|
|
[10]
|
Zeng, H., Yang, Z., Xu, N., et al. (2017) Connective Tissue Growth Factor Promotes Temozolomide Resistance in Glioblastoma through TGF-β1-Dependent Activation of Smad/ERK Signaling. Cell Death and Disease, 8, e2885. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, C., Zhang, X., Xu, R., et al. (2017) TGF-β2 Initiates Au-tophagy via Smad and Non-Smad Pathway to Promote Glioma Cells’ Invasion. Journal of Experimental & Clinical Cancer Research, 36, 162. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Dai, B., Xiao, Z., Mao, B., et al. (2019) lncRNA AWPPH Pro-motes the Migration and Invasion of Glioma Cells by Activating the TGF-β Pathway. Oncology Letters, 18, 5923-5929. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Tang, J., Yu, B., Li, Y., et al. (2019) TGF-β-Activated lncRNA LINC00115 Is a Critical Regulator of Glioma Stem-Like Cell Tumorigenicity. EMBO Reports, 20, e48170. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
May, J.L., Kouri, F.M., Hurley, L.A., et al. (2019) IDH3-α Reg-ulates One-Carbon Metabolism in Glioblastoma. Science Advances, 5, eaat0456. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lei, Z., Liqun, H., Roberta, L., et al. (2018) IDH-Mutation Status Is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas. Neuro-Oncology, 20, 1505-1516.
|
|
[16]
|
Hollon, T.C. and Orringer, D.A. (2018) Shedding Light on IDH1 Mutation in Gliomas. Clinical Cancer Research, 24, 2467-2469. [Google Scholar] [CrossRef]
|
|
[17]
|
Biedermann, J., Preussler, M., Conde, M., et al. (2019) Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers (Basel), 11, E2028. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Philip, B., Yu, D.X., Silvis, M.R., et al. (2018) Mutant IDH1 Promotes Glioma Formation in Vivo. Cell Reports, 23, 1553-1564. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Miller, J.J., Loebel, F., Juratli, T.A., et al. (2019) Accelerated Progression of IDH Mutant Glioma after First Recurrence. Neuro-Oncology, 21, 669-677. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
(2019) IDH Inhibitors Target Common Glioma Mutation. Cancer Discovery, 9, 992. [Google Scholar] [CrossRef]
|
|
[21]
|
Han, Y., Wu, Z., Wu, T., et al. (2016) Tu-mor-Suppressive Function of Long Noncoding RNA MALAT1 in Glioma Cells by Downregulation of MMP2 and In-activation of ERK/MAPK Signaling. Cell Death and Disease, 7, e2123. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Wu, H., Liu, L. and Zhu, J.M. (2019) MiR-93-5p Inhibited Proliferation and Metastasis of Glioma Cells by Targeting MMP2. European Review for Medical and Pharmacological Sciences, 23, 9517-9524.
|
|
[23]
|
Wang, Z., Wang, L., Liang, Z., et al. (2019) Long Non-Coding RNA BCAR4 Promotes Growth, Invasion and Tumorigenicity by Targeting miR-2276 to Upregulate MMP7 Expression in Glioma. OncoTargets and Therapy, 12, 10963-10973. [Google Scholar] [CrossRef]
|
|
[24]
|
Wang, R., Zhang, S., Chen, X., et al. (2018) EIF4A3-Induced Circular RNA MMP9 (circMMP9) Acts as a Sponge of miR-124 and Promotes Glioblastoma Multiforme Cell Tumorigenesis. Molecular Cancer, 17, 166. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Guo, G., Sun, Y., Hong, R., et al. (2019) IKBKE Enhances TMZ-Chemoresistance through Upregulation of MGMT Expression in Glioblastoma. Clinical and Translational On-cology. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Wickström, M., Dyberg, C., Milosevic, J., et al. (2015) Wnt/β-Catenin Pathway Regulates MGMT Gene Expression in Cancer and Inhibition of Wnt Signalling Prevents Chemoresistance. Nature Communications, 6, Article No. 8904. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Yu, Z., Chen, Y., Wang, S., et al. (2018) Inhibition of NF-κB Results in Anti-Glioma Activity and Reduces Temozolomide-Induced Chemoresistance by Down-Regulating MGMT Gene Expression. Cancer Letters, 428, 77-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Bi, Y.M., et al. (2018) β-Catenin Contributes to Cordycepin-Induced MGMT Inhibition and Reduction of Temozolomide Resistance in Glioma Cells by Increasing In-tracellular Reactive Oxygen Species. Cancer Letters, 435, 66-79.
|
|
[29]
|
Natsume, A., Ishii, D., Wakabayashi, T., et al. (2005) IFN-β Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to Temozolomide. Cancer Research, 65, 7573. [Google Scholar] [CrossRef]
|
|
[30]
|
Friedmann-Morvinski, D., Narasimamurthy, R., Xia, Y., et al. (2016) Targeting NF-κB in Glioblastoma: A Therapeutic Approach. Science Advances, 2, e1501292. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Hai, L., Zhang, C., Li, T., et al. (2018) Notch1 Is a Prognostic Factor That Is Distinctly Activated in the Classical and Proneural Subtype of Glioblastoma and That Promotes Glioma Cell Survival via the NF-κB(p65) Pathway. Cell Death & Disease, 9, 158. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Zhang, Y.Y., et al. (2018) Cell-Permeable NF-κB Inhibi-tor-Conjugated Liposomes for Treatment of Glioma. Journal of Controlled Release: Official Journal of the Controlled Release Society, 289, 102-113. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Zhao, H.F., Wang, J.., Jiang, H.R., et al. (2016) PI3K p110β Isoform Synergizes with JNK in the Regulation of Glioblastoma Cell Proliferation and Migration through Akt and FAK Inhibition. Journal of Experimental & Clinical Cancer Research, 35, 78. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Lin, F., de Gooijer, M.C., Hanekamp, D., et al. (2016) PI3K-mTOR Pathway Inhibition Exhibits Efficacy against High-Grade Glioma in Clinically Relevant Mouse Models. Clinical Cancer Research, 23. [Google Scholar] [CrossRef]
|
|
[35]
|
Yu, Z., Xie, G., Zhou, G., et al. (2015) NVP-BEZ235, a Novel Dual PI3K-mTOR Inhibitor Displays Anti-Glioma Activity and Reduces Chemoresistance to Temozolomide in Human Glioma Cells. Cancer Letters, 367, 58-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Xue, S., Hu, M., Iyer, V., et al. (2017) Blocking the PD-1/PD-L1 Pathway in Glioma: A Potential New Treatment Strategy. Journal of Hematology & Oncology, 10, 81. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Ricklefs, F.L., Alayo, Q., Krenzlin, H., et al. (2018) Immune Evasion Mediated by PD-L1 on Glioblastoma-Derived Extracellular Vesicles. Science Advances, 4, eaar2766. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
DiDomenico, J., Lamano, J.B., Oyon, D., et al. (2018) The Immune Checkpoint Protein PD-L1 Induces and Maintains Regulatory T Cells in Glioblastoma. Oncoimmunology; 7, 2162-402X.
|
|
[39]
|
Nduom, E.K., Wei, J., Yaghi, N.K., et al. (2016) PD-L1 Expression and Prognostic Impact in Glio-blastoma. Neuro-Oncology, 18, 195-205. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Gordana, V., Fecci, P.E., David, R., et al. (2015) Programmed Death Ligand 1 (PD-L1) as an Immunotherapy Target in Patients with Glioblas-toma. Neuro-Oncology, 17, 1043-1045. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Hung, A.L., Russell, M., Debebe, T., et al. (2018) TIGIT and PD-1 Dual Checkpoint Blockade Enhances Antitumor Immunity and Survival in GBM. OncoImmunology, 7, e1466769. [Google Scholar] [CrossRef]
|